Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2022-08-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
康芝药业2022年度以简易程序向特定对象发行股票募集资金运用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022年度以简易程序向特定对象发行股票募集资金运用的可行性分析报告" which translates to "2022 Feasibility Analysis Report on the Use of Funds Raised by Private Placement of Shares." It details the investment plan for funds raised through a specific stock issuance, including detailed project descriptions, investment amounts, and R&D plans. The content focuses on the use of raised capital for drug development projects, with no indication of it being an earnings release, annual report, or other financial statement. It is a detailed report analyzing the feasibility and use of capital raised through a financing activity. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content about the capital raising and fund usage, not just an announcement or a brief summary. Hence, it is not a Report Publication Announcement or Regulatory Filing. Confidence is high due to the clear focus on fundraising and capital use.
2022-08-11 Chinese
康芝药业2022年度以简易程序向特定对象发行股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled '2022年度以简易程序向特定对象发行股票方案论证分析报告' which translates to '2022 Annual Simplified Procedure Private Placement of Shares Scheme Demonstration and Analysis Report'. It discusses the background, purpose, pricing, legal compliance, and impact analysis of a private placement of shares by the company 康芝药业股份有限公司. The content includes detailed financial assumptions, regulatory compliance references, and procedural descriptions related to a capital raising event through issuing new shares to specific investors. This is a comprehensive document focused on a capital/financing activity rather than a general annual report, earnings release, or other categories. It is not a brief announcement or a certification but a full analytical report on the capital raising plan. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and depth confirm it is a full report, not just an announcement or summary.
2022-08-11 Chinese
关于公司2022年度以简易程序向特定对象发行股票摊薄即期回报及填补回报措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a specific issuance of shares to particular investors, including the impact on financial metrics, risk warnings, the necessity and rationale for the issuance, and commitments by the company's board and controlling shareholders. It discusses dilution effects, financial assumptions, and measures to mitigate immediate dilution impact. The document references regulatory guidelines and includes detailed financial impact calculations but does not present a full financial report or earnings release. It is focused on capital raising and related disclosures, consistent with a Capital/Financing Update. The document length is over 7,000 characters and contains substantive financial data related to the issuance. Therefore, it is classified as a Capital/Financing Update (CAP).
2022-08-11 Chinese
独立董事关于第五届董事会第二十六次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion statement from independent directors regarding the company's board meeting and related proposals about a simplified procedure for a private placement of shares. It discusses compliance with relevant laws and regulations, the feasibility of the issuance plan, and the impact on shareholders. The document is not a full financial report, earnings release, or audit report. It is a formal opinion related to board decisions and capital raising activities but does not itself announce a financing event or provide financial data. It is not a report publication announcement since it contains substantive content and opinions. The document fits best as a Capital/Financing Update (CAP) because it relates to the company's financing activities and issuance plans, with independent directors' opinions on these matters.
2022-08-11 Chinese
关于公司2022年度以简易程序向特定对象发行股票预案披露提示性公告
Capital/Financing Update Classification · 95% confidence The document is a disclosure announcement regarding a company's plan to issue shares to specific investors using a simplified procedure. It mentions the board meeting approval and references the disclosure on a regulatory website. The document is short (565 characters) and serves as a notice rather than the full detailed report or prospectus of the share issuance. It does not contain financial statements or detailed analysis but announces the capital raising plan and related approvals. Therefore, it fits the category of Capital/Financing Update (CAP).
2022-08-11 Chinese
关于最近五年被证券监管部门和交易所采取监管措施或处罚及整改情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 康芝药业股份有限公司 regarding regulatory measures or penalties taken against the company by securities regulatory bodies and stock exchanges over the past five years. It details a specific regulatory letter issued by the Shenzhen Stock Exchange in 2019 and the company's corrective actions. The document is short (966 characters) and serves as a disclosure of regulatory history rather than a financial report or detailed audit. It does not contain financial statements, earnings data, or management discussion. It is a regulatory compliance announcement related to past regulatory actions and company responses, fitting best under Regulatory Filings (RNS).
2022-08-11 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.